Evidence map›Paper›PMID 38665312›Full record

ArticleCase reports in oncology

A New Sarcoma Shortly after Treatment for High-Grade Glioma with Adjuvant Chemoradiation: A Case Report.

Abdossalam M Madkhali, Hasah F Alaluan, Mohammed H Alnajeim, Eyad F Al Saeed, Abdulrazag M Ajlan, Ahmed Abdelwarith, Ali Abduh, Saleh Albanyan, Ashwag Alqurashi, Hisham Alkhalidi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Abdossalam M MadkhaliDepartment of Medicine, Oncology, Hematology and Radiation Oncology Unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Hasah F AlaluanCollege of Medicine, King Saud University, Riyadh, Saudi Arabia.
Mohammed H AlnajeimCollege of Medicine, King Saud University, Riyadh, Saudi Arabia.
Eyad F Al SaeedDepartment of Medicine, Oncology, Hematology and Radiation Oncology Unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Abdulrazag M AjlanSurgery Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Ahmed AbdelwarithOncology Center, King Saud University, Riyadh, Saudi Arabia.
Ali AbduhDepartment of Radiology, King Khalid University Hospital, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.
Saleh AlbanyanDepartment of Internal Medicine, College of Medicine and King Khalid University Hospital, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.
Ashwag AlqurashiDivision of Neurosurgery, Department of Surgery, King Saud University Medical City, Riyadh, Saudi Arabia.
Hisham AlkhalidiDepartment of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
King Saud University · SAKing Khalid University Hospital · SAKing Saud Medical City · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: High-grade gliomas are central nervous system tumors conventionally treated with surgery followed by adjuvant chemoradiotherapy. Secondary cancer due to radiation therapy is a rare yet established phenomenon that typically occurs years after radiation therapy. Case Presentation: In this case, we discuss an early presentation of a second cancer adjacent to the radiation field. This case report is of a 52-year-old male who developed a new scalp sarcoma at the site of primary surgery 8 months after radiation therapy. Genetic testing revealed a heterozygous missense variant in the Conclusion: Secondary cancers may arise earlier than expected, even in phenotypically normal patients, as they may have unmanifested variants of relevant mutations. The question of pre-radiotherapy screening for radiosensitivity syndromes and diseases requires further study, as current data are limited and do not provide enough insight into the significance of different genetic variants.

Indexed as

ComplicationGlioblastomaHigh-grade gliomaRadiationSarcomaSecondary cancer

Identifiers

PMID38665312
PMCPMC11045215
OpenAlexW4395677868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.